Michael H. Kramer

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Long-read cDNA sequencing reveals novel isoforms and spliceosome-mutant-enriched transcripts in AML and MDS

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-05-21

• Overexpression of the signaling coordinator GAB2 can play an important role in acute myeloid leukemia progression

  Journal of Clinical Investigation · 2025-08-07 · 2 citations

• Recurrent Amplification of Chromosome 7 in Murine AML with <i>Dnmt3a</i>R878H and <i>Npm1</i>cA Mutations Identifies <i>Gab2</i> As a Possible Therapeutic Target in AML

  Blood · 2024-11-05

• Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

  Blood · 2024-11-05 · 1 citations

• VISTA As a Mediator of Immune Suppression in AML Initiated By <i>DNMT3A</i> and <i>NPM1</i> mutations

  Blood · 2024-11-05 · 1 citations

• MPN-755 Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

  Clinical Lymphoma Myeloma & Leukemia · 2024-08-26

• Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

  Clinical Lymphoma Myeloma & Leukemia · 2024-08-26

• Supplementary Figure S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Figure S7 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Figure S3 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Figure S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Data from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Table S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

  2024-08-01

• Supplementary Figure S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Figure S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Figure S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Figure S4 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Methods S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Data from Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskPreprint

  2024-08-01

• Supplementary Table S8 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

  2024-08-01